Radar · Oncology in San Diego
Best Oncology Companies in San Diego, United States
The 177 best Oncology companies in San Diego, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Halozyme.
By Riya SenguptaFinancials
177companies tracked
$11Bdisclosed funding
1unicorns
127have raised
FLIAR INTELLIGENCE · ONCOLOGY × SAN DIEGO
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
86%cloud-native stacks
2025funding peak (by rounds)
2unicorns
2016median founding year
239kcombined LinkedIn audience
36%of audience held by top 3
5companies hiring publicly (12 mo)
Ranked: Best Oncology companies in San Diego
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Halozyme Developer of drug delivery technologies for the treatment of various diseases | $1.3B | 46 mo ago | 373 373 → 536 (+44%) · sector median +44% | Helen Torley CEO & President | WordPressBugHerdApple iCloud Mail+21 | 715 patents Enabling subcutaneous delivery of biologics via hyaluronidase and advanced injector devices | 1 partnership |
| 2 | Biosplice 🦄 Developer of therapeutics modulating alternative splicing for disease treatment | $778M | 62 mo ago | 175 | Richard Schwab Co-Founder | BootstrapMicrosoft ASP.NETAzure+9 | — | — |
| 3 | RayzeBio R&D company focused on manufacturing of cancer drugs | $426M | 45 mo ago | 88 | Deborah Charych Co-Founder & Chief Technology Officer | WordPress Block EditorWordPressApple iCloud Mail+25 | 70 patents Radiopharmaceuticals for targeted imaging and therapy of SSTR‑positive and glypican‑3‑expressing cancers | — |
| 4 | Singlera Genomics Developer of next generation sequencing by methylation haplotyping approach for the detection of cancer | $380M | 66 mo ago | 18 | Yuan Gao Co-Founder & Chairman | — | 32 patents Patents concentrated in chemistry & materials | — |
| 5 | Ambrx Developer of Antibody drug conjugates to treat cancers, metabolic disorders and cardiovascular disorders | $346M | 67 mo ago | 79 | Lawson Macartney President & Ceo | WordPressBugHerdMySQL+26 | 1,276 patents Protein engineering and antibody-drug conjugates for therapeutic biologics | — |
| 6 | Capstan Therapeutics Developer of cell therapies for a broad range of diseases | $340M | 27 mo ago | 75 | Laura Shawver CEO | WordPressTypeScriptGraphQL+21 | — | — |
| 7 | Erasca Developer of small molecule based therapeutics for cancer | $300M | 26 mo ago | 120 120 → 114 (-5%) · sector median +44% | — | DrupalApple iCloud MailPHP+27 | 172 patents Targeted cancer therapeutics: kinase (EGFR, KRAS, ERK, SHP2, ULK1/2) and PRMT5 inhibitors, plus EGFR antibodies. | 1 job opening · 1 award |
| 8 | Sorrento Therapeutics Developer of immuno therapeutics for cancer, inflammation, and autoimmune diseases 67Funding top 20%Patents top 20%Market top 26%Moat top 30% All 12 signals ▾Fundingtop 20% Patentstop 20% Markettop 26% Moattop 30% Innovationtop 32% Growthtop 45% Fin. healthtop 45% Partnerstop 45% Talentbottom 49% Globalbottom 44% Techbottom 31% Newsbottom 27% Funding: Raised $282M across 17 rounds · 17 rounds over 17 yrs (1.0/yr) Patents: 1,073 patents matched (strict assignee match) · 312 filings since 2022 vs 587 in 2017-21 rank vs industry peers · Fliar Intelligence Index 67/100 | $282M | 14 mo ago | 949 | Henry Ji Co-Founder & CEO | — | 1,073 patents Patents concentrated in health & consumer products | — |
| 9 | BlossomHill Therapeutics Provider of the drug for the treatment of oncology and autoimmune disorders 55Funding top 20%Patents top 21%Innovation top 23%Moat top 26% All 7 signals ▾Fundingtop 20% Patentstop 21% Innovationtop 23% Moattop 26% Newsbottom 42% Globalbottom 42% Marketbottom 34% Funding: Raised $260M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) Patents: 133 patents matched (strict assignee match) · 133 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 55/100 | $260M | 6 mo ago | 14 | — | — | 133 patents Patents concentrated in chemistry & materials | 3 job openings |
| 10 | Boundless Bio Developer of therapeutics for cancer by targeting ecDNA | $252M | 37 mo ago | 29 29 → 43 (+48%) · sector median +44% | — | WordPressApple iCloud MailMySQL+17 | — | — |
| 11 | Avenzo Therapeutics Developer of therapeutics for cancer treatment | $223M | 9 mo ago | 8 | Mohammad Hirmand Co-Founder & Chief Medical Officer | — | — | 1 job opening |
| 12 | Iambic Therapeutics Provider of AI-driven drug discovery platform for the treatment of cancer 60Funding top 15%AI top 26%Moat top 31%Talent top 38% All 9 signals ▾Fundingtop 15% AItop 26% Moattop 31% Talenttop 38% Growthtop 45% Marketbottom 43% Newsbottom 43% Techbottom 40% Globalbottom 39% Funding: Raised $206M across 5 rounds · 5 rounds over 5 yrs (1.0/yr) AI: Classified as an AI company · Product described with: ai driven, ai-driven rank vs industry peers · Fliar Intelligence Index 60/100 | $206M | 2 mo ago | 50 | Fred Manby Co-Founder & CTO | WebflowApple iCloud MailMicrosoft 365+13 | — | — |
| 13 | Epic Sciences Provider of non-invasive tests for the detection of circulating tumor cells | $204M | 38 mo ago | 98 | — | — | 145 patents Liquid biopsy technologies for detecting and profiling circulating tumor cells in cancer. | — |
| 14 | VelosBio Developer of therapeutic solutions for the treatment of cancer | $204M | 71 mo ago | 30 | David Johnson CEO | — | 55 patents Targeted cancer therapeutics using ROR1-specific antibody‑drug conjugates and bispecific antibodies | — |
| 15 | MEI Pharma Developer of targeted therapies for the treatment of cancer | $204M | 11 mo ago | 46 46 → 110 (+139%) · sector median +44% | — | — | 329 patents Novel CDK9 inhibitor polymorphs and oncology combination therapies (PI3K/PD‑1). | — |
| 16 | Artiva Developer of therapeutics for autoimmune diseases and cancer | $198M | 63 mo ago | 15 | — | WordPressApple iCloud MailMySQL+22 | 6 patents Architectural floor lighting fixtures with arch-shaped multi‑light designs | — |
| 17 | Solve Therapeutics Developer of antibody-based therapies targeting tumor-specific antigens for cancer treatment 55Funding top 16%Moat top 40%Global top 45%Market bottom 49% All 5 signals ▾Fundingtop 16% Moattop 40% Globaltop 45% Marketbottom 49% Talentbottom 49% Funding: Raised $195M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Moat: Soonicorn · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 55/100 | $195M | 7 mo ago | — | Dave Johnson Founder & CEO | — | — | — |
| 18 | Shoreline Biosciences Developer of cell-based therapeutic solutions for cancer treatment | $183M | 55 mo ago | 98 | Dan Kaufman Co-Founder | Cart FunctionalitySquarespace CommerceSquarespace+17 | — | — |
| 19 | Janux Therapeutics Developer of immunotherapeutics for the treatment of cancer | $181M | 62 mo ago | 59 59 → 121 (+105%) · sector median +44% | David Campbell President | WordPressMySQLPHP+25 | 170 patents Bispecific T‑cell‑engaging antibodies and cleavable linkers for tumor antigen targeting | — |
| 20 | Turnstone Biologics Developer of oncolytic viral immunotherapies for cancer treatment | $172M | 59 mo ago | 80 | John Bell Co-Founder | WordPress Block EditorWordPressApple iCloud Mail+19 | 61 patents Engineered tumor-infiltrating lymphocytes and ex vivo T‑cell expansion for cancer immunotherapy | — |
| 21 | Plexium Precision medicine company pioneering targeted protein degradation therapeutics | $165M | 11 mo ago | 81 | Andrew MacConnell Co-Founder | — | 121 patents Epigenetic protein degraders and oligonucleotide‑encoded small‑molecule discovery platforms | — |
| 22 | BioAtla Developer of immunotherapies for cancer using active biologics platform | $162M | 71 mo ago | 41 41 → 35 (-15%) · sector median +44% | Jay Short Chairman | WordPressMySQLPHP+25 | 698 patents Therapeutic antibodies and engineered proteins for targeted cancer and aging cell treatments | — |
| 23 | Radionetics Developer of radiopharmaceuticals for cancer treatment | $137M | 29 mo ago | 23 | R Struther Founder | Node.jsGSAPVue.js+10 | — | — |
| 24 | Lassen Therapeutics Developer of therapeutics to treat cancer | $116M | 30 mo ago | 6 | Mark Barrett Founder | — | — | — |
| 25 | 858 Therapeutics Developer of small-molecule therapeutics for the treatment of cancer | $110M | 23 mo ago | 25 | Jeffrey Stafford Chief Executive Officer | — | — | — |
| 26 | MBrace Therapeutics Provider of a technology platform for the development of antibody-drug conjugate to treat cancer | $110M | 31 mo ago | — | Isan Chen Co-Founder & CEO | WordPressMySQLPHP+19 | — | — |
| 27 | Adcentrx Therapeutics Developer of next-generation targeted therapies for cancer | $101M | 30 mo ago | 35 | — | — | — | — |
| 28 | Alterome Therapeutics Developer of therapeutics for the treatment of cancer | $99M | 43 mo ago | 14 | Ryan Corcoran Co-Founder | — | — | — |
| 29 | IconOVir Developer of cancer therapeutics using the oncolytic virus | $97M | 36 mo ago | 35 | Mark Mccamish President and CEO | — | — | — |
| 30 | ClearNote Health Developer of non-invasive cancer detection methods 40Moat top 22%Funding top 36%Market top 50%Talent bottom 49% All 5 signals ▾Moattop 22% Fundingtop 36% Markettop 50% Talentbottom 49% Globalbottom 36% Moat: Editorial + unicorn rating 8/10 · Soonicorn Funding: Raised $70.0M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 40/100 | $70M | 0 mo ago | 45 | Dave Mullarkey Chief Executive Officer | — | — | — |
| 31 | Kura Oncology Developer of small molecule drugs for solid tumors and blood cancer | $63M | 28 mo ago | 142 142 → 325 (+129%) · sector median +44% | — | WordPressBugHerdApple iCloud Mail+37 | 483 patents Solid-state forms of farnesyltransferase and menin inhibitors for oncology therapies | 1 award |
| 32 | Primmune Therapeutics Developer of immunotherapies for treating cancer 42Funding top 21%Talent top 28%Product top 35%Innovation top 38% All 8 signals ▾Fundingtop 21% Talenttop 28% Producttop 35% Innovationtop 38% Moattop 39% Techbottom 40% Globalbottom 36% Marketbottom 26% Funding: Raised $46.8M across 8 rounds · 8 rounds over 6 yrs (1.3/yr) Talent: Analyst team rating 4/5 · 4 named leaders on record rank vs industry peers · Fliar Intelligence Index 42/100 | $47M | 4 mo ago | 9 | Stephen Webber Co-Founder | — | — | — |
| 33 | Artelo Biosciences Modifying lipid-signaling pathways to improve cancer treatments 53Funding top 17%Growth top 20%News top 23%Product top 24% All 9 signals ▾Fundingtop 17% Growthtop 20% Newstop 23% Producttop 24% Innovationtop 43% Talenttop 46% Techbottom 46% Globalbottom 38% Marketbottom 24% Funding: Raised $39.9M across 13 rounds · 13 rounds over 8 yrs (1.6/yr) Growth: Web rank 50,000,000 → 10,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 53/100 | $40M | 2 mo ago | 7 | Greg Gorgas CEO & President | WordPressMySQLPHP+16 | — | 1 partnership |
| 34 | Daré Bioscience Developer of non-hormonal pharmaceutical products for female contraceptives 50Funding top 27%Product top 28%Growth top 37%Innovation top 38% All 11 signals ▾Fundingtop 27% Producttop 28% Growthtop 37% Innovationtop 38% Techtop 40% Moattop 48% Talentbottom 49% Newsbottom 45% Fin. healthbottom 43% Marketbottom 33% Globalbottom 32% Funding: Raised $39.7M across 17 rounds · 17 rounds over 9 yrs (1.9/yr) Product: 3 distinct product lines · 1 published app (300 installs) rank vs industry peers · Fliar Intelligence Index 50/100 | $40M | 6 mo ago | 30 30 → 27 (-10%) · sector median +44% | Sabrina Johnson President and CEO | WordPressMySQLPHP+24 | — | 4 launchs |
| 35 | Calidi Biotherapeutics Developer of gene therapies for the treatment of cancer and other indications | $34M | 22 mo ago | 29 29 → 31 (+7%) · sector median +44% | Megan Camaisa Co-Founder | WebflowApple iCloud MailMicrosoft 365+15 | 47 patents Oncolytic viral therapies using cell carriers and engineered smallpox vaccine platforms | 1 launch |
| 36 | Equillium Developer of therapies for treating autoimmune and inflammatory disorders | $30M | 10 mo ago | 36 36 → 38 (+6%) · sector median +44% | Daniel Bradbury Co-Founder & CEO | Q4MediaElement.jsMicrosoft ASP.NET+14 | 33 patents Immunotherapy antibodies targeting CD6 for autoimmune and inflammatory disease treatment | — |
| 37 | Kintara Therapeutics Developer of therapeutic solutions for the treatment of cancer | $29M | 35 mo ago | 3 | — | BootstrapApache HTTP ServerKlaro+9 | — | — |
| 38 | Vironexis Biotherapeutics Developer of AAV-delivered T-cell immunotherapies for the treatment of cancer | $26M | 21 mo ago | — | Timothy Cripe Co-Founder | — | 15 patents AAV-based gene therapy vectors targeting metastatic cancer prevention and treatment | — |
| 39 | SelectION Provider of screening and development platform for drugs 11Funding top 36%Talent bottom 49%Global bottom 37%Market bottom 17% All 4 signals ▾Fundingtop 36% Talentbottom 49% Globalbottom 37% Marketbottom 17% Funding: Raised $15.9M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 11/100 | $16M | 9 mo ago | 2 | Andreas Klostermann Founder & CSO | — | — | — |
| 40 | RyboDyn Developer of immunotherapies for the treatment of cancer 21Talent top 28%Funding top 37%Global bottom 48%Market bottom 15% All 4 signals ▾Talenttop 28% Fundingtop 37% Globalbottom 48% Marketbottom 15% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $14.0M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 21/100 | $14M | 2 mo ago | 3 | Kerry Wilson Co-Founder | — | — | — |
| 41 | Cooler Heads Developer of cold cap system to prevent chemotherapy side effects | $12M | 13 mo ago | — | Kate Dilligan CEO & Founder | WordPressSentryMySQL+25 | 17 patents Thermal management caps and units for medical device cooling applications. | 1 partnership |
| 42 | Abilita Therapeutics Developer of therapeutics to target membrane proteins | $9M | 17 mo ago | — | Mauro Mileni Founder & CEO | WordPressMySQLPHP+11 | — | — |
| 43 | Luxvitae Therapeutics Developer of therapeutics for multiple diseases | $8M | 18 mo ago | — | Mathew Patt Founder | — | — | — |
| 44 | Diagnologix Developer of cell-processing systems to sort circulating tumor cells | $8M | 13 mo ago | — | Yu-Tsueng Liu Founder | — | 13 patents Patents concentrated in chemistry & materials | — |
| 45 | Arima Genomics Developer of technologies for genome sequence and structure | $7M | 11 mo ago | 48 | — | WordPressMySQLPHP+31 | 29 patents Patents concentrated in chemistry & materials | 1 partnership · 1 award |
| 46 | Plex Pharmaceuticals Innovating treatments for complex diseases through targeted drug discovery programs | $6M | 15 mo ago | 3 | — | — | — | — |
| 47 | INmuneBIO Provider of immunotherapeutics for the treatment of multiple conditions | $3M | 17 mo ago | 11 11 → 16 (+45%) · sector median +44% | Raymond Tesi CEO & CMO | JoomlaAwesompletePHP+15 | — | — |
| 48 | Reprogram Biosciences Developer of in vivo cancer cell reprogramming therapies | $1M | 13 mo ago | — | Rustam Esanov Co-Founder & CEO | — | — | — |
| 49 | Aethlon Medical Immunotherapeutic device company combating cancer and life-threatening viral infections | $300K | 6 mo ago | 14 14 → 25 (+79%) · sector median +44% | Charles Fisher CEO | BootstrapApache HTTP ServerAmazon Web Services+9 | — | — |
| 50 | Pensievision Innovative 3D medical imaging technology for healthcare and industrial applications | $100K | 7 mo ago | 10 | Joseph Carson Co-Founder and Chief Technology Officer | — | 3 patents Portable 3D lesion imaging and analysis for remote clinical diagnostics | — |
Top 12 Oncology companies in San Diego
#1
Series C · San Diego, California · founded 2019 · 50 employees$206.2Mraised▾
Series C · San Diego, California · founded 2019 · 50 employees
Provider of AI-driven drug discovery platform for the treatment of cancer. It offers an AI driven discovery platform and has discovered two candidates known as IAM-H1, a highly selective and brain penetrant inhibitor of HER2 and its oncogenic mutants, and IAM-C1 a potential first-in-class selective dual CDK2/4 inhibitor to address unmet needs in terms of therapeutic window and treatment resistance in cell cycle driven cancers.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Funding
top 15%AI
top 26%Moat
top 31%Talent
top 38%Growth
top 45%Market
bottom 43%Funding: Raised $206M across 5 rounds · 5 rounds over 5 yrs (1.0/yr) · Last round Series C (Apr 2026)
AI: Classified as an AI company · Product described with: ai driven, ai-driven
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
Funding rounds
- Apr 2026Series C$27.8M
- Nov 2025Series C$100M
- Apr 2024Series B$50M
- Oct 2023Series B$103.2M
Founders & team
Investors
Ascenta Capital, Abingworth, Nvidia, Illumina Ventures, Shanda, Catalio Capital Management
Tech stack
Apple Icloud MailCloudflareDocusignGoogle Font ApiGoogle Hosted LibrariesHsts
#2
Series D · San Diego, California · founded 2016 · 45 employees$70Mraised▾
Series D · San Diego, California · founded 2016 · 45 employees
Developer of non-invasive cancer detection methods. It offers a 5-hydroxymethylcytosine-based epigenomic platform and cell-free DNA-based assays to measure biological changes in cells and detect cancers with high mortality rates when they respond best to treatment.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Moat
top 22%Funding
top 36%Market
top 50%Talent
bottom 49%Global
bottom 36%Moat: Editorial + unicorn rating 8/10 · Soonicorn
Funding: Raised $70.0M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) · Last round Series D (May 2026)
Market: 45 employees (top 39% of Life Sciences)
Audience (LinkedIn): 6k LinkedIn followers — 2.6% of this cohort's audience
Funding rounds
- May 2025Series C$21.8M
- May 2021Series C$70M
Founders & team
Investors
Pathology Asia Holdings
#3
Series B · San Diego, California · founded 2020 · 14 employees$259.6Mraised▾
Series B · San Diego, California · founded 2020 · 14 employees
Provider of the drug for the treatment of oncology and autoimmune disorders. The company is involved in drug design and development based on small molecules.
Fliar Intelligence Index™ 55how this company ranks against its industry peers
Funding
top 20%Patents
top 21%Innovation
top 23%Moat
top 26%News
bottom 42%Global
bottom 42%Funding: Raised $260M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) · Last round Series B (Nov 2025)
Patents: 133 patents matched (strict assignee match) · 133 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
Innovation: 133 patents (top 21% of patent-holders) · 133 filings since 2022 vs 0 in 2017-21
Audience (LinkedIn): 9k LinkedIn followers — 3.9% of this cohort's audience
Hiring (LinkedIn): 3 hiring posts in 12 mo (public) · momentum +3 · hiring: Principal Programmer, Statistical Programming, Director/Senior Director, Medical Affairs
Funding rounds
- Nov 2025Series B$84.2M
- Dec 2023Series B$100M
- Mar 2021Series A$71M
Investors
Cormorant Asset Management, Orbimed, Vivo Capital, Colt Ventures, Plaisance Capital Management, H&D Asset Management
#4
Public · San Diego, California · founded 2011 · 7 employees$39.9Mraised▾
Public · San Diego, California · founded 2011 · 7 employees
Modifying lipid-signaling pathways to improve cancer treatments. This clinical-stage pharmaceutical manufacturing company focuses on oncology and endocannabinoid modulation. They develop treatments for conditions like cancer anorexia-cachexia syndrome, utilizing CBD, FABP5 inhibitors, and synthetic cannabinoids. Their pipeline includes ART27.13, ART26.12, and ART12.11. They aim to restore vitality and daily function in patients. The company is involved in medical innovation and cancer research, striving to improve the lives of those facing limited options. They are exploring novel non-opioid treatments for persistent pain and addressing stress-induced depression and anxiety symptoms.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Funding
top 17%Growth
top 20%News
top 23%Product
top 24%Innovation
top 43%Talent
top 46%Funding: Raised $39.9M across 13 rounds · 13 rounds over 8 yrs (1.6/yr) · Last round Post IPO (Mar 2026)
Growth: Web rank 50,000,000 → 10,000,000 YoY · Fresh capital in last 24 mo
News: 8 BI events in 12 mo (of 19 tracked, 6 types) · +700% YoY · 2 high-value events (IPO/M&A/funding/contracts) in 12 mo
Audience (LinkedIn): 2k LinkedIn followers
Activity (LinkedIn): 1 partnerships (incl. AI Leader ScienceMachine) announced in 12 mo
Funding rounds
- Mar 2026Post IPO$11M
- Jan 2026Post IPO$500K
- Oct 2025Post IPO$3.7M
- Aug 2025Post IPO$9.5M
Founders & team
Investors
National Cancer Institute
Tech stack
Apache Http ServerBootstrapFancyboxGodaddyGoogle AnalyticsGoogle Font Api
#5
Series D · San Diego, California · founded 2021$195Mraised▾
Series D · San Diego, California · founded 2021
Developer of antibody-based therapies targeting tumor-specific antigens for cancer treatment. The company focuses on advancing antibody-based therapeutics to address unmet medical needs. It refines a chemistry platform while developing targeted radionuclide therapeutics. The company evaluates companion radiodiagnostics for use with other types of targeted cancer therapeutics.
Fliar Intelligence Index™ 55how this company ranks against its industry peers
Funding
top 16%Moat
top 40%Global
top 45%Market
bottom 49%Talent
bottom 49%Funding: Raised $195M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) · Last round Series D (Nov 2025)
Moat: Soonicorn · 10 curated direct competitors tracked
Global: Investors from 3 countries beyond United States
Audience (LinkedIn): 2k LinkedIn followers
Funding rounds
- Nov 2025Series D$120M
- Dec 2024Series C$75M
Founders & team
Investors
Yosemite, Abingworth, Ally Bridge Group, B Capital, Balyasny Asset Management, Merck
#6
Series B · San Diego, California · founded 2017 · 9 employees$46.8Mraised▾
Series B · San Diego, California · founded 2017 · 9 employees
Primmune Therapeutics is developing immunotherapies for treating cancer. They are developing a small molecule (orally administered) which is a toll-like receptor 7 (TLR7) agonist (an endosomal innate immune sensor capable of detecting single-stranded ribonucleic acid) helps in systemic activation of innate immunity. It gets expressed on plasmacytoid dendritic cells.
Fliar Intelligence Index™ 42how this company ranks against its industry peers
Funding
top 21%Talent
top 28%Product
top 35%Innovation
top 38%Moat
top 39%Tech
bottom 40%Funding: Raised $46.8M across 8 rounds · 8 rounds over 6 yrs (1.3/yr) · Last round Series B (Jan 2026)
Talent: Analyst team rating 4/5 · 4 named leaders on record · 4 C-suite/founder profiles curated
Product: 3 distinct product lines · Company stage: Series B
Funding rounds
- Jan 2026Series B$8.6M
- Nov 2021Series A$8.4M
- Jan 2021Series A$4M
- Oct 2020Series A$27.4M
Founders & team
Investors
CAM Capital, BioBrit, BioRock Ventures, Bioqube Ventures, Polaris Partners, Samsara BioCapital
Tech stack
WordpressMysqlPhpDownload MonitorContact Form 7Yoast Seo
#7
Series B · San Diego, California · founded 2022 · 8 employees$223.4Mraised▾
Series B · San Diego, California · founded 2022 · 8 employees
Developer of therapeutics for cancer treatment. It offers a pipeline of oncology therapies which include AVZO-021 is a selective inhibitor of CDK2 for advanced solid tumors and HR+/HER2-negative metastatic breast cancer, ARTS-023 is a selective CDK4 inhibitor for HR+ breast cancer, AVZO-1418 is a BsADC targeting EGFR and HER3 for non-small cell lung cancer, and VAC-103 BsADC targeting Nectin4 and TROP2 for urothelial and breast cancers.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 8k LinkedIn followers — 3.2% of this cohort's audience
Hiring: 1 hiring post in 12 mo (public)
Funding rounds
- Aug 2025Series B$60M
- Nov 2024Series A—
- Sep 2022Series A$385.9M
Founders & team
Investors
New Enterprise Associates, Deep Track Capital, Sofinnova Investments, Sands Capital, INCE Capital, TF Capital
#8
Public · San Diego, California · founded 2000 · 46 employees$203.6Mraised▾
Public · San Diego, California · founded 2000 · 46 employees
Developer of targeted therapies for the treatment of cancer. The portfolio of drug candidates includes Pracinostat, an oral HDAC inhibitor for the treatment of elderly patients with newly diagnosed acute myeloid leukemia (AML) for the treatment of Myelodysplastic Syndrome, Myelofibrosis. The pipeline also includes ME-401, a highly selective oral PI3K delta inhibitor that is being developed for the treatment of B-Cell Malignancies such as recurrent CLL or follicular NHL, and ME-344, a novel mitochondrial inhibitor for the treatment of HER2-negative breast cancer.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 5k LinkedIn followers — 2.0% of this cohort's audience
Funding rounds
- Jul 2025Post IPO$100M
- May 2018Post IPO$75M
- Nov 2012Post IPO$27.5M
- May 2011Post IPO$1.1M
Investors
Vivo Capital, New Leaf Venture Partners, RA Capital Management, Three Arch Partners, CAM Capital, New Enterprise Associates
Tech stack
CloudflareHttp/3
#9
Public · San Diego, California · founded 2005 · 30 employees$39.7Mraised▾
Public · San Diego, California · founded 2005 · 30 employees
DARE BIOSCIENCE is a developer of non-hormonal pharmaceutical products for female contraceptives. Their lead candidate, Ovaprene, is an intravaginal non-hormonal ring, that can provide contraceptive protection over several weeks. The design of the ring has a permeable mesh in the centre of the ring that creates a partial barrier to sperm, and a mechanism to release locally acting spermiostatic agents through the ring. The spermiostatic agents are ascorbic acid and ferrous gluconate, which create pH buffering and immobilization of sperm.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Funding
top 27%Product
top 28%Growth
top 37%Innovation
top 38%Tech
top 40%Moat
top 48%Funding: Raised $39.7M across 17 rounds · 17 rounds over 9 yrs (1.9/yr) · Last round Grant (prize money) (Nov 2025)
Product: 3 distinct product lines · 1 published app (300 installs) · Company stage: Public
Growth: Headcount 28 → 30 (+7%) across vintages · Revenue +10429% YoY · Web rank 50,000,000 → 5,000,000 YoY
Audience (LinkedIn): 6k LinkedIn followers — 2.6% of this cohort's audience
Activity (LinkedIn): 4 product launches announced in 12 mo
Funding rounds
- Nov 2025Grant (prize money)$3.6M
- Feb 2025Grant (prize money)$2.3M
- Dec 2024Grant (prize money)$1M
- Jan 2024Grant (prize money)$750K
Founders & team
Investors
NICHD, Gates, NIH, HHS
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAmazon Web Services
#10
Series B · San Diego, California · founded 2017 · 81 employees$165Mraised▾
Series B · San Diego, California · founded 2017 · 81 employees
Precision medicine company pioneering targeted protein degradation therapeutics. This is a next-generation targeted protein degradation (TPD) company focused on rationally designing and discovering Monovalent Direct Degraders and Molecular Glues. Through its comprehensive best-in-class TPD platform powered by a proprietary ultra-high throughput cell-based screening (uHTS) technology, it is pushing the boundaries of TPD. The company is committed to delivering life-changing medicines to patients through a differentiated platform of proprietary technologies and approaches to establish a robust and diverse portfolio of monovalent targeted protein degrader therapeutics. The company is focused on rational design and discovery, and is developing therapeutics for patients in need.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 6k LinkedIn followers — 2.6% of this cohort's audience · 49 engagements/post (2.4× cohort median)
Funding rounds
- Jul 2025Series B$60.1M
- Feb 2022Series B$102M
- Jan 2021Series A$35M
- Oct 2019Series A$28M
Founders & team
Investors
Lux Capital, The Column Group, DCVC, Pivotal bioVenture Partners, RA Capital Management, Citadel
#11
Public · San Diego, California · founded 1989 · 949 employees$281.6Mraised▾
Public · San Diego, California · founded 1989 · 949 employees
Developer of immuno therapeutics for cancer, inflammation, and autoimmune diseases. The company’s lead products are multiple biosimilars and bio better antibodies as well as clinical CAR-T therapies targeting solid tumors. Also, has a portfolio of immuno-oncology antibody programs targeting EGFR, TNF-alpha, CD 25, and IGE. Its lead CAR-T cell therapies are against the carcinoembryonic antigen and prostate-specific membrane antigen.
Fliar Intelligence Index™ 67how this company ranks against its industry peers
Funding
top 20%Patents
top 20%Market
top 26%Moat
top 30%Innovation
top 32%Growth
top 45%Funding: Raised $282M across 17 rounds · 17 rounds over 17 yrs (1.0/yr) · Last round Post IPO (Apr 2025)
Patents: 1,073 patents matched (strict assignee match) · 312 filings since 2022 vs 587 in 2017-21 · Latest publication 2026
Market: 949 employees (top 9% of Immunotherapy) · Revenue ~$62.8M · ~13% of tracked Immunotherapy revenue (13 cos, FY2026)
Funding rounds
- Apr 2025Post IPO$47.4M
- Sep 2018Conventional Debt—
- Jun 2018Post IPO$150M
- Nov 2016Venture Debt$50M
Founders & team
Investors
Aisling Capital, Yuhan Corporation, Hercules Capital, Ally Bridge Group, FREJOY Investment Management, Beijing Shijilongxin Investment
Tech stack
WordpressMysqlPhpTwenty FourteenYoast SeoNginx
#12
Seed · San Diego, California · founded 2022 · 3 employees$14Mraised▾
Seed · San Diego, California · founded 2022 · 3 employees
Developer of immunotherapies for the treatment of cancer. The company has developed antigen discovery and validation platform to create a transformative medicines for patients with cancer.
Fliar Intelligence Index™ 21how this company ranks against its industry peers
Talent
top 28%Funding
top 37%Global
bottom 48%Market
bottom 15%Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Funding: Raised $14.0M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) · Last round Seed (Mar 2026)
Global: Investors from 2 countries beyond United States
Audience (LinkedIn): 1k LinkedIn followers
Funding rounds
- Mar 2026Seed$10M
- Jan 2025Seed$4M
- Jun 2023Seed—
Founders & team
Investors
EvoNexus, Genedant, SeaX Ventures, SOSV, Swell
Funding & investor landscape
$11Btotal disclosed funding
125companies funded
529disclosed rounds
3rounds last 90 days
Most active investors
Notable founders
Fred Manby
Co-Founder & CTO · Iambic Therapeutics
Thomas Miller
Co-Founder & CEO · Iambic Therapeutics
Dave Mullarkey
Chief Executive Officer · ClearNote Health
Greg Gorgas
CEO & President · Artelo Biosciences
Dave Johnson
Founder & CEO · Solve Therapeutics
Stephen Webber
Co-Founder · Primmune Therapeutics
James Appleman
Co-Founder & CSO · Primmune Therapeutics
Mohammad Hirmand
Co-Founder & Chief Medical Officer · Avenzo Therapeutics
Athena Countouriotis
Co-Founder & CEO · Avenzo Therapeutics
Sabrina Johnson
President and CEO · Daré Bioscience
Andrew MacConnell
Co-Founder · Plexium
Henry Ji
Co-Founder & CEO · Sorrento Therapeutics
Prism market signals · United States · country-scoped Prism corpus, 1,572,524 docs
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · United States
How research on Oncology & Cancer Therapeutics is moving in the United States
A read on the academic research around Oncology & Cancer Therapeutics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 12,968 United States-affiliated papers.
research sentiment over time
200820172026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and intensifying — the enthusiastic (strongly-positive) share moved 52% → 67% across 2008–2026.
top research entities
- Harvard University573
- The University of Texas MD Anderson Cancer Center559
- Dana-Farber Cancer Institute413
- Johns Hopkins University356
- Cornell University352
leading researchers
Yang Liu · Yu Zhang · Hinda Najem · Wenxue Ma · Yan-Ruide Li · Murad Novruzov · Waseem Ullah Khan · Ullah Khan Inam
▲
Breakthroughs4,499 · 35%
▲ 32%→35% share
▲1.1× share momentum0 median citations90% since 2021mostly methods-led
Tumor microenvironment research is surging — US breakthrough papers rose from 124 to 1,921.
rising sub-themes (early→recent)
- Tumor microenvironment124→1921
- Immune system80→1464
- Immunotherapy66→1342
- Cancer research197→1345
- Cancer immunotherapy35→714
Newly emergingFlow cytometry 0→48 · Gene 0→45 · Hepatocellular carcinoma 0→42
Landmark Cancer immunotherapy using checkpoint blockade · 6,497 cites
◆
Advancements5,898 · 45%
▲ 44%→46% share
▲1.0× share momentum1 median citations89% since 2021mostly empirical
Cancer immunotherapy advancements are intensifying — US advancement papers scaled from 73 to 718.
rising sub-themes (early→recent)
- Tumor microenvironment212→2712
- Immune system142→2161
- Immunotherapy146→1778
- Cancer research238→1815
- Cancer immunotherapy73→718
Newly emergingBiomarker 0→106 · Epigenetics 0→82 · Gene 0→54
Landmark The Senescence-Associated Secretory Phenotype: The Dark Side of Tumor Suppression · 4,937 cites
▼
Concerns1,469 · 11%
▼ 13%→11% share
▼0.8× share momentum3 median citations85% since 2021mostly reviews
Immunotherapy safety concerns are mounting — related concern papers grew from 42 to 624.
rising sub-themes (early→recent)
- Immunotherapy42→624
- Tumor microenvironment65→585
- Immune system31→529
- Cancer immunotherapy27→298
- Cancer research49→277
Newly emergingOvarian cancer 0→30 · Immunogenicity 0→27 · Transcriptome 0→26
Landmark A framework for advancing our understanding of cancer-associated fibroblasts · 3,630 cites
RESEARCH HOTSPOTS · United States
Where oncology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Boston1020 · +0.56
New York829 · +0.56
SF Bay Area480 · +0.57
Chicago409 · +0.54
Philadelphia355 · +0.57
Los Angeles275 · +0.59
San Diego274 · +0.59
Pittsburgh235 · +0.55
Ann Arbor223 · +0.63
Atlanta204 · +0.54
PATENT SIGNAL · United States
Who's filing oncology patents in the United States
United States oncology patent filing is accelerating — 2,574 filings from 797 assignees (2016–2025), led by Bristol Myers Squibb, IO Therapeutics, UNIV California; annual filings 108→277.
2,574 filings797 assigneespeak 362/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- Bristol Myers Squibb105
- IO Therapeutics91
- UNIV California88
- DANA Farber Cancer INST87
- Memorial Sloan Kettering Cancer 74
- Baylor College Medicine63
- UNIV Texas61
- Editas Medicine47
Common questions
How many Oncology companies are there in San Diego, United States?
Radar tracks 177 indexable Oncology companies headquartered in San Diego, United States that meet our profile-completeness bar.
What is the total funding raised by Oncology companies in San Diego, United States?
The Oncology companies in San Diego, United States on this list have raised a combined $11B in disclosed equity funding across 125 funded companies.
Which is the highest-funded Oncology company in San Diego, United States?
Halozyme is the highest-funded Oncology company in San Diego, United States, with $1.3B in disclosed equity funding.
How many Oncology companies in San Diego, United States are funded?
125 of the 177 Oncology companies in San Diego, United States on this list have disclosed at least one equity funding round.
How many Oncology unicorns are there in San Diego, United States?
1 Oncology company in San Diego, United States on this list is valued at $1B or more.
Who are the top investors in San Diego, United States Oncology companies?
The most active investors in San Diego, United States Oncology companies on this list include HHS, Orbimed, Alexandria, Citadel, Colt Ventures.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.